Allergan plc Stock price

Equities

AGN

IE00BY9D5467

Pharmaceuticals

Delayed Nyse 5-day change 1st Jan Change
- USD -.--% Intraday chart for Allergan plc +1.73% +0.97%
Sales 2018 15.79B Sales 2019 16.09B Capitalization 62.76B
Net income 2018 -5.1B Net income 2019 -5.27B EV / Sales 2018 4.24 x
Net Debt 2018 21.89B Net Debt 2019 17.3B EV / Sales 2019 4.98 x
P/E ratio 2018
-8.76 x
P/E ratio 2019
-11.9 x
Employees -
Yield 2018
2.15%
Yield 2019
1.55%
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21 CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic) CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM® CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics CI
PatientFi Expands Partnership with Allergan Aesthetics CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million. CI
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting CI
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia CI
Allergan plc entered into a definitive agreement to acquire Soliton, Inc. for approximately $510 million. CI
More news
Managers TitleAgeSince
Director of Finance/CFO 54 16-11-30
President 53 20-05-07
Members of the board TitleAgeSince
President 53 20-05-07
Director/Board Member - 20-05-07
Director/Board Member - 20-05-07
More insiders
Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock Allergan plc - Nyse